{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:19:13Z","timestamp":1792401553630,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T00:00:00Z","timestamp":1550275200000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.trecan.2017.12.007","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T17:48:22Z","timestamp":1518803302000},"page":"119-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":282,"title":["Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment"],"prefix":"10.1016","volume":"4","author":[{"given":"Mansi","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2017.12.007_bib0005","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.clinthera.2016.03.021","article-title":"Alarmins and antitumor immunity","volume":"38","author":"Nie","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.trecan.2017.12.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2017.02.019","article-title":"Dendritic cells display subset and tissue-specific maturation dynamics over human life","volume":"46","author":"Granot","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-3606-9_1","article-title":"Review of mouse and human dendritic cell subsets","volume":"1423","author":"Segura","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2006.04.017","article-title":"Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming","volume":"25","author":"Allan","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.it.2004.09.013","article-title":"Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity","volume":"25","author":"Carbone","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0035","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1172\/JCI81137","article-title":"Dendritic cell-derived exosomes for cancer therapy","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2017.12.007_bib0040","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/ni854","article-title":"Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes","volume":"3","author":"Thery","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011144","article-title":"CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells","volume":"5","author":"Yewdall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2017.12.007_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coi.2017.06.003","article-title":"Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines","volume":"47","author":"Saxena","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.182.1.255","article-title":"Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes","volume":"182","author":"Porgador","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0060","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/nm1295-1297","article-title":"Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity","volume":"1","author":"Mayordomo","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.183.1.87","article-title":"Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines","volume":"183","author":"Zitvogel","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/978-1-4615-2930-9_102","article-title":"Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma","volume":"329","author":"Flamand","year":"1993","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0075","first-page":"97","article-title":"Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy","volume":"109","author":"O\u2019Neill","year":"2005","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djr514","article-title":"Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer","volume":"104","author":"Huber","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2017.12.007_bib0085","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/djs279","article-title":"Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer","volume":"104","author":"Kantoff","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2017.12.007_bib0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cr.2016.149","article-title":"Innate immune signaling and regulation in cancer immunotherapy","volume":"27","author":"Corrales","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1100791","article-title":"Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay","volume":"5","author":"Verronese","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0115","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","article-title":"Dendritic cells in cancer: the role revisited","volume":"45","author":"Veglia","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nri3499","article-title":"Metalloproteinases and their natural inhibitors in inflammation and immunity","volume":"13","author":"Khokha","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.4586","article-title":"Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis","volume":"237","author":"Brown","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0135","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-016-1859-9","article-title":"Modulation of innate immunity in the tumor microenvironment","volume":"65","author":"Gonzalez-Gugel","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.celrep.2014.10.067","article-title":"Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses","volume":"9","author":"Godefroy","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2011.01.037","article-title":"Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway","volume":"19","author":"Godefroy","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4161\/onci.1.1.17994","article-title":"Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2","volume":"1","author":"Godefroy","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0155","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","article-title":"Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling","volume":"13","author":"Tang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0160","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-03-705780","article-title":"Immunoregulatory roles of versican proteolysis in the myeloma microenvironment","volume":"128","author":"Hope","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2017.12.007_bib0165","first-page":"5066","article-title":"Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells","volume":"58","author":"Hiltbold","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0170","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.4049\/jimmunol.165.7.3730","article-title":"The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells","volume":"165","author":"Hiltbold","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0175","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.175.3.1628","article-title":"Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity","volume":"175","author":"Carlos","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00262-010-0935-9","article-title":"A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings","volume":"60","author":"Oudard","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0185","doi-asserted-by":"crossref","DOI":"10.1038\/srep31740","article-title":"Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential","volume":"6","author":"Lohmueller","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2017.12.007_bib0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri.2016.112","article-title":"Immunoregulation by members of the TGFbeta superfamily","volume":"16","author":"Chen","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0200","doi-asserted-by":"crossref","first-page":"10635","DOI":"10.1007\/s13277-014-2627-0","article-title":"Macrophage colony-stimulating factor and cancer: a review","volume":"35","author":"Chockalingam","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","article-title":"The paradoxical role of IL-10 in immunity and cancer","volume":"367","author":"Mannino","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2017.12.007_bib0210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1590\/0074-0276130252","article-title":"Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation","volume":"109","author":"Marti","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.trecan.2017.12.007_bib0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.intimp.2014.02.027","article-title":"Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells","volume":"20","author":"Song","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0220","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.20050463","article-title":"Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0225","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00262-004-0652-3","article-title":"Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system","volume":"54","author":"Weber","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2017.12.007_bib0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","article-title":"CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy","volume":"23","author":"Ries","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0240","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.trecan.2017.12.007_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/srep15918","article-title":"IL-10-producing CD4+ T cells negatively regulate fucosylation of epithelial cells in the gut","volume":"5","author":"Goto","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0250","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0255","doi-asserted-by":"crossref","first-page":"OF4","DOI":"10.1158\/2159-8290.CD-NB2016-125","article-title":"Durable responses achieved with AM0010","volume":"6","author":"Rose","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2017.12.007_bib0260","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","article-title":"Lipid accumulation and dendritic cell dysfunction in cancer","volume":"16","author":"Herber","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0265","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","article-title":"ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis","volume":"161","author":"Cubillos-Ruiz","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0270","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1098802","article-title":"Targeting abnormal ER stress responses in tumors: a new approach to cancer immunotherapy","volume":"5","author":"Cubillos-Ruiz","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0275","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targeting cancer-derived adenosine: new therapeutic approaches","volume":"4","author":"Young","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2017.12.007_bib0280","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-15-0095","article-title":"Tumoral immune resistance mediated by enzymes that degrade tryptophan","volume":"3","author":"van Baren","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14737140.2017.1316197","article-title":"Targeting adenosine in cancer immunotherapy: a review of recent progress","volume":"17","author":"Whiteside","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.trecan.2017.12.007_bib0290","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coph.2017.05.002","article-title":"The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO","volume":"35","author":"Mondanelli","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052875","article-title":"Transcriptional profiling of human dendritic cell populations and models \u200b\u2013 unique profiles of in vitro dendritic cells and implications on functionality and applicability","volume":"8","author":"Lundberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2017.12.007_bib0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imm.12117","article-title":"Human dendritic cell subsets","volume":"140","author":"Collin","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0305","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0310","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-3606-9_2","article-title":"In vitro generation of human XCR1+ dendritic cells from CD34+ hematopoietic progenitors","volume":"1423","author":"Balan","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0320","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-04-0602","article-title":"Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma","volume":"10","author":"Di Nicola","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T","article-title":"Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells","volume":"86","author":"Mackensen","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2017.12.007_bib0330","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0335","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4049\/jimmunol.173.4.2780","volume":"173","author":"Ratzinger","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5966\/sctm.2013-0070","article-title":"Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response","volume":"3","author":"Zeng","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0345","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1189\/jlb.0208092","article-title":"Human dendritic cell line models for DC differentiation and clinical DC vaccination studies","volume":"84","author":"Santegoets","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13287-015-0160-8","article-title":"Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy","volume":"6","author":"Kumar","year":"2015","journal-title":"Stem Cell Res. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.trecan.2017.12.007_bib0355","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/S0264-410X(02)00382-1","article-title":"A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy","volume":"20","author":"Lee","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.trecan.2017.12.007_bib0360","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2003-05-1643","article-title":"CCL19\/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2","volume":"103","author":"Scandella","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2017.12.007_bib0365","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The role of CD40 and CD154\/CD40L in dendritic cells","volume":"21","author":"Ma","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0370","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0375","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00262-008-0489-2","article-title":"Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration","volume":"57","author":"Boullart","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0380","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"Okada","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-0345-0_1","article-title":"Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules","volume":"1139","author":"Benteyn","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0390","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00262-014-1558-3","article-title":"Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula","volume":"63","author":"Van Lint","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0395","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.4049\/jimmunol.1201008","article-title":"Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70","volume":"191","author":"Pen","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0400","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0405","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-011-1176-2","article-title":"Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient","volume":"61","author":"Van Nuffel","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0410","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/imm.12264","article-title":"Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells","volume":"142","author":"Gonzalez","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0415","first-page":"663","article-title":"Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines","volume":"6","author":"Vandenberk","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.imlet.2017.01.014","article-title":"2003-2013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer","volume":"183","author":"Lin","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.trecan.2017.12.007_bib0425","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/cncr.30606","article-title":"Phase 1\/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma","volume":"123","author":"Miwa","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2017.12.007_bib0430","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Chiang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0435","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/2326-6066.CIR-13-0084","article-title":"Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells","volume":"1","author":"Clancy-Thompson","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0440","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.vaccine.2015.02.019","article-title":"Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.trecan.2017.12.007_bib0445","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0450","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00262-016-1905-7","article-title":"Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma","volume":"65","author":"Akasaki","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0455","doi-asserted-by":"crossref","first-page":"E828","DOI":"10.3390\/ijms17060828","article-title":"Dendritic-tumor fusion cell-based cancer vaccines","volume":"17","author":"Koido","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2017.12.007_bib0460","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2017.12.007_bib0470","first-page":"970","article-title":"Mutation-derived tumor antigens: novel targets in cancer immunotherapy","volume":"29","author":"Finnigan","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0475","doi-asserted-by":"crossref","first-page":"262","DOI":"10.21037\/atm.2016.06.17","article-title":"Neoantigen-based cancer immunotherapy","volume":"4","author":"Bobisse","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0480","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0490","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061324","article-title":"Immune checkpoints as a target for colorectal cancer treatment","volume":"18","author":"Passardi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2017.12.007_bib0500","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2017.12.007_bib0505","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","author":"Chang","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0510","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0515","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2017.12.007_bib0520","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0525","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0530","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00262-012-1272-y","article-title":"Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naive T-cell subtypes","volume":"61","author":"Moeller","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0535","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2011-08-373944","article-title":"The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells","volume":"119","author":"Schreibelt","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2017.12.007_bib0540","first-page":"5231","article-title":"Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen","volume":"9","author":"Saluja","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.trecan.2017.12.007_bib0545","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0550","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9589","article-title":"A phase II randomized study of CDX-1401, a dendritic cell targeting NY-ESO-1 vaccine, in patients with malignant melanoma pre-treated with recombinant CDX-301, a recombinant human Flt3 ligand","volume":"34","author":"Bhardwaj","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0555","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1038\/cti.2016.6","article-title":"Targeting dendritic cells: a promising strategy to improve vaccine effectiveness","volume":"5","author":"Macri","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0560","article-title":"Dendritic cell targeting vaccine for HPV-associated cancer","volume":"3","author":"Yin","year":"2016","journal-title":"Cancer Cell Microenviron."},{"key":"10.1016\/j.trecan.2017.12.007_bib0565","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1158\/0008-5472.CAN-16-2089","article-title":"CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations","volume":"77","author":"Nimanong","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0570","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1500078","article-title":"Human anti-CD40 antibody and poly IC:LC adjuvant combination induces potent T cell responses in the lung of nonhuman primates","volume":"195","author":"Thompson","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0575","doi-asserted-by":"crossref","DOI":"10.1038\/srep15262","article-title":"Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells","volume":"5","author":"Zeng","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0580","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/gt.2015.43","article-title":"Lentivirus-induced \u2018smart\u2019 dendritic cells: pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma","volume":"22","author":"Sundarasetty","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.trecan.2017.12.007_bib0585","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.0105-2896.2004.00139.x","article-title":"Cancer immunotherapy with mRNA-transfected dendritic cells","volume":"199","author":"Gilboa","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2017.12.007_bib0590","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2217\/imt-2016-0116","article-title":"Next-generation dendritic cell-based vaccines for leukemia patients","volume":"9","author":"Hoffmann","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trecan.2017.12.007_bib0595","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0600","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-015-0572-3","article-title":"Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting","volume":"13","author":"Lipson","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0605","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0610","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann. Surg."},{"key":"10.1016\/j.trecan.2017.12.007_bib0615","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0620","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fphar.2017.00126","article-title":"Dual functional capability of dendritic cells \u2013 cytokine-induced killer cells in improving side effects of colorectal cancer therapy","volume":"8","author":"Mosinska","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0625","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3892\/ol.2016.4273","article-title":"Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer","volume":"11","author":"Zhang","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.trecan.2017.12.007_bib0630","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0635","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-014-1575-2","article-title":"A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma","volume":"63","author":"Poschke","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2017.12.007_bib0640","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-017-0394-x","article-title":"Chimeric antigen receptor therapy in acute lymphoblastic leukemia clinical practice","volume":"12","author":"Luskin","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.trecan.2017.12.007_bib0645","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0650","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.12.007_bib0655","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0660","doi-asserted-by":"crossref","first-page":"15154","DOI":"10.1073\/pnas.1517584112","article-title":"Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells","volume":"112","author":"Tanne","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.12.007_bib0665","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah5509","article-title":"Tumor-derived exosomes modulate PD-L1 expression in monocytes","volume":"2","author":"Haderk","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0670","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1090077","article-title":"Pharmacological DNA demethylation: implications for cancer immunotherapy","volume":"5","author":"Roulois","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.12.007_bib0675","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0680","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1034\/j.1600-0463.2003.11107812.x","article-title":"Against the self: dendritic cells versus cancer","volume":"111","author":"Cho","year":"2003","journal-title":"Acta Pathol. Microbiol. Immunol. Scand."},{"key":"10.1016\/j.trecan.2017.12.007_bib0685","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-immunol-041015-055254","article-title":"The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules","volume":"35","author":"Cruz","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0690","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.immuni.2015.11.006","article-title":"Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens","volume":"43","author":"Alloatti","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0695","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12432","article-title":"Dendritic cell maturation and cross-presentation: timing matters!","volume":"272","author":"Alloatti","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2017.12.007_bib0700","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2014.04.054","article-title":"TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation","volume":"158","author":"Nair-Gupta","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.12.007_bib0705","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature09863","article-title":"Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection","volume":"471","author":"Wakim","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0710","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.12.007_bib0715","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.trecan.2017.12.007_bib0720","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/978-1-4939-3387-7_44","article-title":"Dendritic cell vaccines","volume":"1403","author":"Sabado","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0725","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.immuni.2008.08.006","article-title":"Mechanisms and consequences of dendritic cell migration","volume":"29","author":"Alvarez","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0730","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/icb.2015.29","article-title":"Moving to the suburbs: T-cell positioning within lymph nodes during activation and memory","volume":"93","author":"Groom","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0735","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2012.07.011","article-title":"Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes","volume":"37","author":"Gerner","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0740","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.immuni.2015.07.020","article-title":"Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection","volume":"43","author":"Hor","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0745","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.immuni.2013.08.034","article-title":"Antigen availability determines CD8+ T cell-dendritic cell interaction kinetics and memory fate decisions","volume":"39","author":"Henrickson","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0750","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nature02238","article-title":"T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases","volume":"427","author":"Mempel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0755","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.immuni.2014.12.024","article-title":"Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens","volume":"42","author":"Gerner","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0760","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.it.2013.06.001","article-title":"Inflammatory dendritic cells in mice and humans","volume":"34","author":"Segura","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2017.12.007_bib0765","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","article-title":"Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species","volume":"45","author":"Guilliams","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.12.007_bib0770","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.12.007_bib0775","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317302406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317302406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:48:39Z","timestamp":1762505319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803317302406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2405803317302406"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2017.12.007","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}